Stock Runners : Regulus Therapeutics Inc. (NASDAQ:RGLS), American Airlines Group Inc. (NASDAQ:AAL), H&R Block, Inc. (NYSE:HRB), Allergan Inc. (NYSE:AGN), Marine Products (NYSE:MPX)

Regulus Therapeutics Inc. (NASDAQ:RGLS) announced that it has commenced an underwritten public offering, subject to market and other conditions, to issue and sell approximately $80,000,000 of shares of its common stock, of which approximately $70,000,000 of shares are being offered by Regulus and approximately $10,000,000 of shares are being offered by an existing stockholder of Regulus, Isis Pharmaceuticals, Inc. Regulus Therapeutics Inc. (NASDAQ:RGLS) belongs to … Continue reading Stock Runners : Regulus Therapeutics Inc. (NASDAQ:RGLS), American Airlines Group Inc. (NASDAQ:AAL), H&R Block, Inc. (NYSE:HRB), Allergan Inc. (NYSE:AGN), Marine Products (NYSE:MPX)

John Meady10/28

Active Watch List : Advanced Micro Devices, Inc. (NYSE:AMD), Itau Unibanco Holding SA (ADR) (NYSE:ITUB), Regulus Therapeutics Inc. (NASDAQ:RGLS), MMI, ADC

Advanced Micro Devices (NYSE:AMD ) and Taiwan Semiconductor ( TSM ) will be reporting next week and will shed more light on the near-term outlook for the chip space. Advanced Micro Devices, Inc. (NYSE:AMD) belongs to Technology sector. Its net profit margin is 1.40% and weekly performance is -20.00%. On last trading day company shares ended up $2.72. Advanced Micro Devices, Inc. (NYSE:AMD) distance from … Continue reading Active Watch List : Advanced Micro Devices, Inc. (NYSE:AMD), Itau Unibanco Holding SA (ADR) (NYSE:ITUB), Regulus Therapeutics Inc. (NASDAQ:RGLS), MMI, ADC

John Bellich10/13

Hot Alert : Mylan (NASDAQ:MYL), Weyerhaeuser (NYSE:WY), First Merchants Corporation (NASDAQ:FRME), Applied Genetic Technologies Corporation (NASDAQ:AGTC), Regulus Therapeutics Inc. (NASDAQ:RGLS)

Citigroup downgraded Mylan, Inc. (NASDAQ:MYL) to Neutral citing a lack of near-term catalysts ahead of the tax inversion deal closing. Citi lowered its price target for shares to $57 from $61. Mylan, Inc. (NASDAQ:MYL)’s stock on 30 July traded at beginning with a price of $50.77and when day-trade ended the stock finally moved up 0.30% to end at $50.55. Mylan, Inc. (NASDAQ:MYL)’s showed weekly performance … Continue reading Hot Alert : Mylan (NASDAQ:MYL), Weyerhaeuser (NYSE:WY), First Merchants Corporation (NASDAQ:FRME), Applied Genetic Technologies Corporation (NASDAQ:AGTC), Regulus Therapeutics Inc. (NASDAQ:RGLS)

Adam Keintzel07/3107/31

Bearsih Stocks at NASDAQ: Geospace Technologies (NASDAQ:GEOS), Regulus Therapeutics (NASDAQ:RGLS), Tile Shop Hldgs, Inc. (NASDAQ:TTS), Leading Brands, Inc (USA) (NASDAQ:LBIX)

In trading on Thursday, shares of Geospace Technologies Corp (NASDAQ:GEOS) entered into oversold territory, hitting an RSI reading of 29.9, after changing hands as low as $45.52 per share. Geospace Technologies Corp (NASDAQ:GEOS) stock performance was -7.98% in last session and finished the day at $45.57. Traded volume was 478,472.00million shares in the last session and the average volume of the stock remained 232.04K shares. … Continue reading Bearsih Stocks at NASDAQ: Geospace Technologies (NASDAQ:GEOS), Regulus Therapeutics (NASDAQ:RGLS), Tile Shop Hldgs, Inc. (NASDAQ:TTS), Leading Brands, Inc (USA) (NASDAQ:LBIX)

Kristen Barton07/11

FB Nasdaq FB Facebook

Biotech decliners: Aldeyra Therapeutics Inc (NASDAQ:ALDX), Uniqure NV (NASDAQ:QURE), Regulus Therapeutics Inc (NASDAQ:RGLS), Genetic Technologies Limited (ADR) (NASDAQ:GENE)

Aldeyra Therapeutics Inc (NASDAQ:ALDX) Director C. Boyd Clarke purchased 12,500 shares of the stock in a transaction dated Wednesday, May 7th. The stock was purchased at an average price of $8.00 per share, with a total value of $100,000.00. Following the acquisition, the director now directly owns 12,500 shares in the company, valued at approximately $100,000. Aldeyra Therapeutics Inc (NASDAQ:ALDX) stock performance was -8.31% in … Continue reading Biotech decliners: Aldeyra Therapeutics Inc (NASDAQ:ALDX), Uniqure NV (NASDAQ:QURE), Regulus Therapeutics Inc (NASDAQ:RGLS), Genetic Technologies Limited (ADR) (NASDAQ:GENE)

Colin Pettis05/22